



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/807,234	04/06/2001	Tae-Shin Park	0136/OJ067	3081
7278	7590	08/30/2005	EXAMINER TUNG, JOYCE	
DARBY & DARBY P.C. P. O. BOX 5257 NEW YORK, NY 10150-5257			ART UNIT 1637	PAPER NUMBER

DATE MAILED: 08/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief	Application No. 09/807,234	Applicant(s) PARK ET AL.	
	Examiner Joyce Tung	Art Unit 1637	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 29 June 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. ☐ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a) ☒ The period for reply expires 3 months from the mailing date of the final rejection.
- b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☒ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
- (a) ☒ They raise new issues that would require further consideration and/or search (see NOTE below);
- (b) ☐ They raise the issue of new matter (see NOTE below);
- (c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
- (d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: PLEASE THE ATTACHED. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. ☐ Applicant's reply has overcome the following rejection(s): _____.

6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. ☒ For purposes of appeal, the proposed amendment(s): a) ☒ will not be entered, or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: 36-38.

Claim(s) rejected: claims 25, 27-29, 31-35.

Claim(s) withdrawn from consideration: 12-24.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. ☐ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: _____.

12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). _____

13. ☐ Other: _____.

Art Unit: 1637

The applicant's amendment filed June 29, 2005 was not entered. Claims 12-25, 27-29, 31-38 are pending.

1. The newly added language "glass slide to which the probes are attached" raise new issue, which requires further consideration and search.
2. Without entering the newly added language, claims 25, 28 and 30 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Gravitt et al. (J. Clin. Microbiol. 1998, vol. 36(10) pg. 3020-3027), in view of the Stratagene Catalog, 1988), Claim 29 remains rejected under 35 U.S.C. 103(a) as being unpatentable over Gravitt et al. (J. Clin. Microbiol. 1998, vol. 36(10) pg. 3020-3027), in view of the Stratagene Catalog, 1988), as applied to claims 25, 28 and 30 above and further in view of PCT international application WO 95/22626, Claim 27 remains rejected under 35 U.S.C. 103(a) as being unpatentable over Gravitt et al. (J. Clin. Microbiol., 1998, vol. 36(10) pg. 3020-3027), in view of the Stratagene Catalog, 1988), as applied to claims 25, 28 and 30 above, and further in view of Bevan et al. (Biochem J., 1990, Vol. 267(1), pg. 119-123), Claim 31 remains rejected under 35 U.S.C. 103(a) as being unpatentable over Gravitt et al. (J. Clin. Microbiol., 1998, vol. 36(10) pg. 3020-3027), in view of the Stratagene Catalog, 1988), as applied to claims 25, 28 and 30 above, and further in view of Sena et al. (5,273,881), Claims 32-35 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Gravitt et al. (J. Clin. Microbiol., 1998, vol. 36(10) pg. 3020-3027), in view of the Stratagene Catalog, 1988), as applied to claims 25, 28 and 30 above, and further in view of published U.S. patent application 2003/001295 to Shalon ("Shalon").
3. The rejection of claims 32-33 and 35 under 35 U.S.C. 103(a) as being unpatentable over Gravitt et al. (J. Clin. Microbiol., 1998, vol. 36(10) pg. 3020-3027), in view of the Stratagene

Art Unit: 1637

Catalog, 1988), as applied to claims 25, 28 and 30 above, and further in view of Zammattéo et al. (Analytical biochemistry, 2000, Vol. 280, pg. 143-150) is withdrawn because of the argument.

4. Claims 25, 27-29, 31-38 remain objected because the claims 25, 27-29 and 31-35 amended add SEQ ID NO: 2-19 which was not elected in Applicants' response, filed on December 16, 2003 in which Applicants' elected Group III, claims 25-35 and SEQ ID NO: 1 and 24-25 and the newly added claims 36-38 also have non-elected SEQ ID NO: 2-19.

Summary

5. No claims are allowable.

6. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

August 23, 2005


KENNETH R. HORLICK, PH.D.
PRIMARY EXAMINER

8/24/05